This is a working overview of somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
=== Pharmacokinetics === The two active components of the medication, ibuprofen and hydrocodone, do not affect each other's absorption characteristics or other pharmacokinetic parameters. After an oral dose, the peak level of hydrocodone in the blood is reached 1.7 hours after administration. The blood levels of ibuprofen peak 1.8 hours after oral administration.
According to AASLD guidelines, a liver biopsy may be considered in people with MASLD who are at increased risk of having steatohepatitis with or without advanced fibrosis, but only when all other competing chronic liver diseases are excluded (such as alcoholic liver disease). The presence of metabolic syndrome, MASLD Fibrosis Score (FIB-4), or liver stiffness (as measured by Vibration-controlled transient elastography or MRE) can identify individuals who are at higher risk of steatohepatitis or advanced fibrosis.
=== Free radical === The deamination of an alanine molecule produces the free radical CH3C•HCO2−. Deamination can be induced in solid or aqueous alanine by radiation that causes homolytic cleavage of the carbon–nitrogen bond. This property of alanine is used in dosimetric measurements in radiotherapy. When normal alanine is irradiated, the radiation causes certain alanine molecules to become free radicals, and, as these radicals are stable, the free radical content can later be measured by electron paramagnetic resonance in order to find out how much radiation the alanine was exposed to. This is considered to be a biologically relevant measure of the amount of radiation damage that living tissue would suffer under the same radiation exposure. Radiotherapy treatment plans can be delivered in test mode to alanine pellets, which can then be measured to check that the intended pattern of radiation dose is correctly delivered by the treatment system.
On 2 September 2025, Trump said that the US had struck a boat carrying unspecified illegal drugs, alleging it was operated by the Tren de Aragua. Trump said that the strike killed 11 "narcoterrorists". On 28 November, it was revealed that two men who survived the initial strike were killed in subsequent strikes. A second strike occurred on 15 September, killing three. The US government did not provide evidence that those killed in either strike were narco-trafficking. In a third strike on 19 September that killed three, the Dominican Republic later stated it had cooperated with the US Navy in a first-ever joint operation to locate the boat and salvage 377 packages of cocaine, weighing 1,000 kilograms (2,200 lb). On 3 October, a strike on a vessel near the coast of Venezuela killed four; anonymous US officials later declared that there were Colombians on at least one of the boats. Trump stated on 14 October that six more were killed in a strike near the coast of Venezuela. Reuters reported that another previously unannounced strike on 16 October had killed two and included two survivors who were being held on a Navy ship. By 19 October, both were repatriated to their respective countries of origin, Colombia and Ecuador. On 17 October, three were killed in a strike on an alleged drug vessel operated by the National Liberation Army (ELN) of Colombia. The ELN denied involvement in any drug boat trafficking. The first strike at night, on 24 October against an alleged drug vessel operated by Tren de Aragua in the Caribbean, killed six.
== History == The existence of the ribosomal tunnel became apparent in the 1960s. When the nascent protein was exposed to hydrolytic enzymes, part of the protein was protected from hydrolysis, supporting the hypothesis of the existence of a tunnel that shields part of the protein. The tunnel was then identified in the large subunit of the ribosome by cryogenic electron microscopy. Crucial information about the existence of the tunnel was provided by atomically resolved structures of the large ribosomal subunit determined by X-ray crystallography by the research group of Thomas Steitz. In 2009, Thomas Steitz, along with A. Yonath and V. Ramakrishnan, received the Nobel Prize in Chemistry for their research on the ribosome. The initial view that the tunnel is merely an inert environment through which the nascent polypeptide exits the ribosome has been abandoned based on numerous studies. Today, it is believed that the tunnel is actively involved in regulating translation and maintaining homeostasis.
Sources: en.wikipedia.org
Fish maw (Chinese: 魚肚, yúdǔ; Yue Chinese: 花胶, fa kau; Mandarin Chinese: 花膠, huājiāo) or "sea ginseng" is a delicacy in Chinese cuisine, particularly Zhejiang cuisine. Consumption of fish maw in China may go back to the Han Dynasty, c. 206 BCE-220 CE. The History of the Southern Dynasties documents fish maw soaked in honey being served in royal court during the Northern and Southern dynasties period, c. 420-589 CE. Consumption of rockfish fish maw was documented in the 6th century Qimin Yaoshu. Fish maw is one of the four sea delicacies of Chinese cuisine, along with abalone, sea cucumber, and shark's fin. Fish maw from larger fish species is more prestigious; the restaurant trade buys smaller maw. Fish maw from male fish is preferred for its relative thickness and resilience to dissolving. Until the late 20th century, the Chinese bahaba or giant yellow croaker Bahaba taipingensis of the China Seas was the premier source of fish maw. However, overfishing has driven the Chinese bahaba population to near-extinction, and raised demand for similar fish, particular the related Sciaenidae. Fish maw, particularly of rare fish, is highly valued in traditional Chinese medicine. TCM practitioners recommend fish maw for the post-partum period and recovering from surgery. It is also valued as a cosmetic: its high level of collagen is believed to improve one's skin. As of 2016, Southern China and Hong Kong had the largest demand for fish maw.
==== Cough ==== Codeine was once viewed as the "gold standard" in cough suppressants, but this position has since been questioned. Some recent placebo-controlled trials have found that it may be no better than a placebo for some causes including acute cough in children. As a consequence, it is not recommended for children. Additionally, there is no evidence that hydrocodone is useful in children. Similarly, a 2012 Dutch guideline regarding the treatment of acute cough does not recommend its use. Low dose morphine may help chronic cough but its use is limited by side effects.
The Welsh Romance Peredur son of Efrawg is based on Chrétien or derived from a common original, but it contains several prominent deviations and lacks a Grail. The character of the Fisher King appears (though he is not called such) and presents Peredur with a severed head on a platter. Peredur later learns that he was related to that king, and that the severed head was that of his cousin, whose death he must avenge by defeating the Nine Witches.
"Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome". European Journal of Endocrinology. 158 (6): 793–801. doi:10.1530/EJE-07-0857. PMID 18322300. Jensterle, Mojca; Janez, Andrej; Vrtovec, Bojan; Meden-Vrtovec, Helena; Pfeifer, Marija; Prezelj, Janez; Kocjan, Tomaz (2007). "Decreased Androgen Levels and Improved Menstrual Pattern after Angiotensin II Receptor Antagonist Telmisartan Treatment in Four Hypertensive Patients with Polycystic Ovary Syndrome: Case Series". Croatian Medical Journal. 48 (6): 864–70. doi:10.3325/cmj.2007.6.864. PMC 2213810. PMID 18074422. Silič, Anja; Janež, Andrej; Tomažič, Janez; Karner, Primož; Vidmar, Ludvik; Sharma, Prem; Matičič, Mojca (2007). "Effect of Rosiglitazone and Metformin on Insulin Resistance in Patients Infected with Human Immunodeficiency Virus Receiving Highly Active Antiretroviral Therapy Containing Protease Inhibitor: Randomized Prospective Controlled Clinical Trial". Croatian Medical Journal. 48 (6): 791–9. doi:10.3325/cmj.2007.6.791. PMC 2213797. PMID 18074413. Steiner, Charles A.; Janez, Andrej; Jensterle, Mojca; Reisinger, Katrin; Forst, Thomas; Pfützner, Andreas (2007). "Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome". Journal of Diabetes Science and Technology. 1 (2): 211–7. doi:10.1177/193229680700100212. PMC 2771474. PMID 19888409. Mlinar, B; Marc, J; Janez, A; Pfeifer, M (2007).
Sources: en.wikipedia.org
=== Part One === Part One is set during the second half of events of Half-Life 2: Episode One. Dr. Isaac Kleiner is making his "Kleinercasts" on City 17's PA system, warning that the Combine Citadel is set to explode at any moment; should the Citadel detonate, the resulting explosion will destroy the city and the surrounding area. Prior to the film's events, Gordon Freeman's actions within the Citadel have held down the impending explosion, opening a small window of time for civilians to escape. Members of the Lambda Resistance are seen fighting their way out of the city as the Combine's Civil Protection forces try to hold them back. CP officers are also seen executing captured rebels, while Combine synths wreak havoc on the warzone. Two male Resistance members (Derek Chan and Ian Purchase) are introduced escaping through an overrun trainyard. Through radio communication, the two learn from a third rebel (David Purchase) that the last evacuation train has already left, and are urged to escape the city on foot through the canal system (a route similar to that of Gordon Freeman's in Half-Life 2) in order to catch up with David, who is en route to the Resistance stronghold of White Forest. After a brief argument, the two resolve to escape City 17 before "the Citadel blows us up first". Suddenly, CP officers appear and fire on the Resistance members. The two retaliate with their own weaponry (Derek using a 9mm pistol, then a crowbar found hanging on a handrail; Ian using an SMG with a grenade launcher) and manage to escape.
K2CO3 + CO2 + H2O → 2 KHCO3 CO2 de-scrubber: The above potassium carbonate solution (enriched with CO2) is then sent to the CO2 de-scrubber where CO2 is de-scrubbed by stepwise (usually two steps) flashing. The first step is done to remove the hydrocarbon gases, and the second step is employed to strip off CO2.
Sandler (10 January 1927 – 6 October 1998), South African Jewish British psychoanalyst within the Anna Freud Grouping – now the Contemporary Freudians – of the British Psychoanalytical Society; perhaps best known for what has been called his 'silent revolution' in re-aligning the concepts of the object relations school within the framework of ego psychology; editor of the International Journal of Psycho-Analysis and President of the International Psychoanalytical Association; was the first Sigmund Freud Professor of Psychoanalysis at the Hebrew University of Jerusalem. Philippe Sands, KC (born 17 October 1960), writer, journalist and lawyer 11 King's Bench Walk; Director of the Centre on International Courts and Tribunals; counsel and advocate before many international courts and tribunals, including the International Court of Justice, the International Tribunal for the Law of the Sea, the European Court of Justice, the European Court of Human Rights and International Criminal Court;serves on panel of International Centre for the Settlement of Investment Disputes (CAS).; is author of seventeen books on international law as well as writing a number of geo-political texts; served as President of English PEN; appointed Professor of Law at Harvard Law School; co-founder of the Centre for International Environmental Law; and the Project on International Courts and Tribunals (1997); served as a Commissioner on the UK Government Commission on a Bill of Human Rights. Donald Sassoon (b.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.